Merck Acquires Calporta Therapeutics for ~$576M

 Merck Acquires Calporta Therapeutics for ~$576M

Merck Acquires Calporta Therapeutics for ~$576M

Shots:

  • Merck acquired Calporta, in the all-cash transaction making a total deal value ~$576M including an up front payment and contingent milestone payments
  • The focus of the collaboration is to gain a preclinical portfolio of small-molecule TRPML1 agonists which are being evaluated for lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease
  • Avalon Ventures and GSK launched Calporta in 2015 as part of their collaborative effort to found up to 10 biotech companies. TRPML1 is a lysosomal ion channel, by activating it signaling with small molecules could re-establish lysosomal processes and restore cellular function

Click here to­ read full press release/ article | Ref: Businesswire | Image: Bloomberg

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post